These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3883504)

  • 21. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
    Hainsworth JD; Stroup SL; Greco FA
    Cancer; 1996 Jun; 77(12):2458-63. PubMed ID: 8640693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
    Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Phase I clinical study of NK 171 (etoposide)].
    Kimura K; Yamada K; Niitani H
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):851-6. PubMed ID: 2985006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
    Bunn PA; Kelly K
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
    Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
    Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of etoposide for carcinoma of the prostate.
    Walther PJ; Williams SD; Troner M; Greco FA; Birch R; Einhorn LH
    Cancer Treat Rep; 1986 Jun; 70(6):771-2. PubMed ID: 3524825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials.
    Felip E; Massuti B; Camps C; Benito D; Isla D; González-Larriba JL; López-Cabrerizo MP; Salamanca O; Puerto-Pica J; Moyano A; Baselga J; Rosell R
    Clin Cancer Res; 1998 Nov; 4(11):2723-8. PubMed ID: 9829735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
    Isobe T; Fukuoka M; Negoro S; Sugiura T; Kawahara M; Kudoh S; Araki J; Nakagawa K; Yokozaki M; Yamakido M; Ariyoshi Y
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1091-6. PubMed ID: 10945001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
    Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G
    J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experiences with VP-16 in combination with cyclophosphamide or adriamycin in the anaplastic, predominantly small cell bronchogenic carcinoma].
    Schmieder HA; Jungi WF; Mayr AC; Senn HJ
    Schweiz Med Wochenschr; 1979 Jun; 109(22):841-4. PubMed ID: 462156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report.
    Bonomi P; Faber LP; Recine D; Lincoln S
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):42-7. PubMed ID: 7644927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer.
    Ghielmini M; Pagani O; de Jong J; Pampallona S; Conti A; Maestroni G; Sessa C; Cavalli F
    Br J Cancer; 1999 Jun; 80(7):1058-61. PubMed ID: 10362116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.
    Slayton RE; Creasman WT; Petty W; Bundy B; Blessing JA
    Cancer Treat Rep; 1979; 63(11-12):2089-92. PubMed ID: 526942
    [No Abstract]   [Full Text] [Related]  

  • 36. Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
    Issell BF; Einhorn LH; Comis RL; Lawson RD; Baker LH; Harvey HA; Lanzotti VA; Wampler GL; Daniels JR; Anderson PN
    Cancer Treat Rep; 1985 Jan; 69(1):127-8. PubMed ID: 2981617
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase I trial of a new form of an oral administration of VP-16-213.
    Lau ME; Hansen HH; Nissen NI; Pedersen H
    Cancer Treat Rep; 1979 Mar; 63(3):485-7. PubMed ID: 371801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.
    Eagan RT; Carr DT; Frytak S; Rubin J; Lee RE
    Cancer Treat Rep; 1976 Jul; 60(7):949-51. PubMed ID: 64298
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
    Jungi WF; Senn HJ; Beckmann C; Flury R; Frei P; Holdener E
    Schweiz Med Wochenschr; 1975 Oct; 105(42):1365-9. PubMed ID: 179137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate.
    Anderson G; Bowyer F; Williams L
    Thorax; 1981 Jun; 36(6):462-4. PubMed ID: 7314017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.